Danyelza Injection Naxitamab-gqggk 40 Mg, API Form : Liquid

Danyelza Injection  Naxitamab-gqggk 10 ml Vial Neuroblastoma   Danyelza is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.